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VOLUME 49 | NUMBER 8 | AUGUST 2017 Nature GeNetics A r t i c l e S lack of reproducibility in knockout experiments is a well-documented challenge in drug-target development and behavioral and other translational studies 2, 3 . This lack of reproducibility is commonly due to using poorly defined statistical methods, performing studies in only one sex and practicing bias in animal selection 4 . The development of a comprehensive reference phenotype database by using fully validated, standardized and automated phenotyping procedures across all body systems in mutants of both sexes provides a robust dataset to corroborate disease-causing factors in humans.
The International Mouse Phenotyping Consortium (IMPC) is creating just such a catalog of mammalian gene function that systematically associates mouse genotype-to-phenotype data and enables researchers to formulate hypotheses for biomedical and translational research as well as purpose-driven preclinical studies 5, 6 . The IMPC adult phenotyping pipeline analyzes cohorts of male and female knockouts on an isogenic C57BL/6N background from embryonic-stem-cell resources produced by the International Knockout Mouse Consortium comprising targeted null mutations with reporter-gene elements [7] [8] [9] . Homozygotes are characterized, except in those strains (approximately 30%) in which gene inactivation necessitates the use of heterozygotes to study mice that are embryonic/perinatal lethal or subviable 10, 11 . The pipeline measures a total of 509 phenotyping parameters that encompass diverse biological and disease areas including neurological, behavioral, metabolic, cardiovascular, pulmonary, reproductive, respiratory, sensory, musculoskeletal and immunological parameters. Standardized and harmonized protocols developed by the IMPC are used to decrease phenotypic variance across the centers and build upon experience from the pilot EUMODIC project, in which a limited 7% discordant-phenotype rate has been observed for a large set of 22 common reference mutant lines 6 . Rigorous data quality control is applied to the captured data from the ten phenotyping centers, and an automated statistical analysis pipeline (PhenStat 12 ; Online Methods) identifies mutants with statistically significant phenotypic abnormalities.
In the current IMPC data release 5.0 (2 August 2016), 3,328 genes have been fully or partially phenotyped, thus generating over 20 million data points and 28,406 phenotype annotations. Complementing the physiological, behavioral and structural phenotype datasets, the IMPC also provides annotated expression of LacZ data across multiple organ and tissue systems for 1,413 genes 13 and extensive histopathological analysis of adult tissues for 333 genes 14 . The IMPC portal (URLs) provides a single point of access to phenotype data, embryonic-stem-cell and Cas9-RNA-guided nuclease resources and mutant mouse strains. Sophisticated query interfaces for both gene and phenotype data are provided, as well as tools to visualize phenotypes encompassing quantitative, categorical and image data 15 . Periodic data releases provide the most recent genotype-phenotype associations.
In our current analysis, we (i) identified new mouse models for human mendelian disorders with a known genetic basis, (ii) uncovered candidate disease-associated genes for human mendelian disorders for which only a genomic location had been associated and (iii) identified new mouse disease models involving genes with little or no previous functional annotation. A summary of the results is presented in Figure 1 and is described in more detail in the following sections.
RESULTS

Comparison of IMPC findings with previous knowledge
We first investigated the concordance of our phenotype annotations with previously reported data for mouse lines involving the same genes. We found that 621 genes assessed by us have previous mouse-model annotations, on the basis of a literature review of knockout lines by the Mouse Genome Informatics (MGI) group 1 . An assessment of the corresponding 2,547 MGI gene-phenotype associations previously assessed by an IMPC procedure showed that 958 (38%) were detected, and 62% (385 out of 621) of the genes had at least one phenotype reproduced (Supplementary Table 1 ). This result was is in line with previous reports describing the reproducibility of biomedical models 16 . A lack of reproducibility may be due to several factors including different genetic backgrounds and variations in experimental techniques and statistical methods. For example, evidence for the previously reported increase in circulating glucose in Gad2 mice was found in our data (URLs) but was not considered statistically valid by our robust methods. Despite our best efforts to be as broad based as possible in the context of a high-throughput project, there were an additional 10,068 MGI phenotypes for these genes that we were unable to assess or that would have required a different type of allele to be introduced to observe the effect. However, as shown below, our pipeline covers all major disease areas. Additionally, use of our resources by the research community to publish over 1,300 new publications is generating numerous new annotations from MGI's curation of the literature and upcoming changes to our pipeline, such as phenotyping a subset of genes in mice at later ages (12-18 months) and including new behavioral tests, will increase our coverage. Furthermore, we generated extensive new knowledge: 90% (8,984 of 9,942) of the gene-phenotype annotations described by IMPC have not previously been described in the literature.
Models of human mendelian disease
The high volume and complexity of data produced by the IMPC present challenges for identifying relevant models of human diseases. To facilitate discovery, we developed a translational pipeline to Human disease models were identified by measuring the degree of phenotypic similarity between IMPC null mutant mouse strains and their orthologous genetic loci associated with human diseases. Models of mendelian disease: of 889 potential disease models, 360 mutant strains had both phenotypic overlap and an orthologous null allele, as compared with diseases with known mutations described in OMIM and Orphanet. Novel mendelian disease candidates: 135 strains had phenotypic overlap and null alleles syntenic to linkage or cytogenetic regions associated with human diseases with unknown molecular mechanisms. New functional knowledge: of 2,564 genes with a nonlethal IMPC phenotype, IMPC data provided new functional experimental evidence for 1,092 of these genes, on the basis of GO annotation.
automatically detect phenotypic similarities between the IMPC strains and over 7,000 rare diseases described in the Online Mendelian Inheritance in Man (OMIM) 17 and Orphanet databases 18 . The pipeline utilizes the human phenotype ontology (HPO) 19 annotations for rare diseases, maintained by the Monarch Initiative 20 , our Mammalian Phenotype Ontology (MP) 21 annotations of phenotypic abnormalities and the PhenoDigm algorithm, which has also been developed by the Monarch Initiative 22 . The methodology is based on previous work demonstrating superior identification of disease models, as compared with defining mouse strains solely by orthology or using other methods of calculating phenotype similarity 22 , and the results provide a quantitative measure of how well an adult mouse model recapitulates the clinical features of a disease.
From the ~15% of mouse protein-coding genes phenotyped by IMPC to date, 889 known rare disease-gene associations represented within OMIM and Orphanet have an orthologous IMPC mouse strain and display at least one phenotype (Supplementary Table 2 ). By comparing human and mouse phenotypes, our automated pipeline identified 185 adult disease-gene associations for which the IMPC mutant mouse strain modeled the human disease; most associations (134) involved genes for which a mutant mouse strain either had not been generated or had not been reported as a model of that disease, on the basis of the MGI curation ( Table 1 and Supplementary Tables 2  and 3 ). Each of the 889 associations had a mean of 14.7 ± 27.8 (mean ± s.d.) candidate genes associated with the disease, on the basis of the algorithm, with a median rank of 3 for the true associated gene in the 185 sets of recalled associations.
The range of human mendelian diseases with matching mouse phenotypes was broad and included multiple biological systems ( Table 2) . Three examples of mouse models that, to our knowledge, have not previously been reported (Fig. 2) are for Bernard-Soulier syndrome, type C (MIM231200), Bardet-Biedl syndrome-5 (MIM615983) and Gordon Holmes syndrome (MIM212840). Bernard-Soulier syndromes are bleeding disorders that result from mutations in genes . WT, wild type. In a, female control, n = 479 mice; female homozygous, n = 8; male control, n = 428; male homozygous, n = 8; linear mixed-effects model without weight, P = 0. In b, female control, n = 439; female homozygous, n = 8; male control, n = 428; male homozygous, n = 8; linear mixed-effects model without weight, P = 2.31 × 10 −6 ). Asterisks, significant difference between mutant and same-sex controls; mixed-effects-model P < 0.0000. (c,d) Bbs5: Bbs5 is associated with Bardet-Biedl syndrome (BBS). Bbs5 tm1b(EUCOMM)Wtsi homozygotes have increased body-fat percentage (c) and impaired glucose tolerance (d). In c, female control, n = 1,276; female homozygous, n = 8; male control, n = 1,296; male homozygous, n = 8; linear mixed-effects model without weight, P = 1.99 × 10 −11 ). In d, blood glucose levels were determined after a 16-h fast followed by intraperitoneal glucose injection. Female control, n = 491; female homozygous, n = 8; male control, n = 509; male homozygous, n = 8; linear mixed-effects model without weight, P = 2.85 × 10 −7 ). X-ray visualization of Bbs5 homozygotes and controls. In a-d, box limits, first and third quartiles; line, median; whiskers, minimum and maximum values. (e,f) Rnf216: Gordon Holmes syndrome is associated with Rnf216 and is characterized by hypogonadism and cerebellar ataxia. (e) X-ray image of a 14-week-old Bbs5 homozygous-null female mouse shows the large body size of this strain compared with an age-matched, wild-type control. (f) Rnf216 tm1b(EUCOMM)Wtsi homozygous-null male mice are infertile. Histopathology images (20× magnification) show seminiferoustubule degeneration and atrophy with Leydig-cell hyperplasia and epididymal aspermia in null mice, as compared with the unaffected seminiferous tubules and epididymis in control mice. Scale bars, 100 µm.
encoding protein products of the glycoprotein Ib complex, which serves as the platelet-membrane receptor for von Willebrand factor. Glycoprotein Ib is composed of four subunits encoded by four separate genes, GP1BA, GP1BB, GP9 and GP5, and mutations in all these genes are associated with an autosomal recessive (AR) disorder characterized by prolonged bleeding times, enlarged platelets, an inability to clot and incomplete penetrance of thrombocytopenia 23 . Gp9 tm1.1(KOMP)Vlcg null homozygotes have a decreased number of platelets and larger cell volumes (Fig. 2a,b) , thus recapitulating key features of the disease and adding evidence that the point mutations associated with disease in humans lead to a functionally null complex. Bardet-Biedl syndromes are heterogeneous AR ciliopathies characterized by retinitis pigmentosa, obesity, kidney dysfunction, polydactyly, behavioral dysfunction and hypogonadism. The disorder is associated with at least 19 genes whose products form the BBSome, a protein complex involved in signaling-receptor trafficking within cilia and that may also have functions not involving cilia 24 . Twenty mutations including splice-site, missense/nonsense, insertion, indel and deletion mutations within the BBS5 gene account for 4% of all BBS cases. Bbs5 tm1b(EUCOMM)Wtsi null mice exhibit abnormal retinal morphology resembling the retinal dystrophy observed in Bardet-Biedl syndrome. Other phenotypes were also observed in null mice recapitulating many hallmarks of BBS, including obesity (Fig. 2c,e) as well as other features such as impaired glucose homeostasis (Fig. 2d) . Gordon Holmes syndrome is another AR disorder characterized by hypogonadism and cerebellar ataxia, and it has been associated with RNF216 (refs. 25,26) . Male infertility was observed in Rnf216 tm1b(EUCOMM)Wtsi homozygousnull mice with histopathology identifying seminiferous-tubule degeneration and atrophy characterized by the diffuse absence of most or all germ cells and the presence of occasional multinucleated spermatids with pyknotic nuclei within tubules lined by vacuolated Sertoli cells. Seminiferous changes were accompanied by diffuse interstitial cell (Leydig cell) hyperplasia. The epididymis was devoid of spermatozoa (epididymal aspermia) (Fig. 2f) .
From the 704/889 known associations for which we did not detect an IMPC model, 48 have not yet been tested in mice for a phenotype recapitulating any of the clinical phenotypes, thus leaving 656 (74%) associations for which our automatic algorithm did not detect a potential disease phenotype from the IMPC pipeline. To evaluate the sensitivity of the automated human-mouse phenotype matching, we manually evaluated 100 randomly chosen examples of these missed associations (Supplementary Table 4 ). This process led to 12 additional discoveries for which the phenotype matches fell below the similarity threshold used in our algorithm, e.g., the decreased startlereflex match for deafness. PhenoDigm is optimized to maximize precision and recall (Supplementary Fig. 1) , and decreasing our threshold to detect such matches would have introduced many false positives. Manual assessment is not feasible in the long term, given the ever-increasing number of strains and new data for existing strains. However, future implementations will incorporate histopathological data to increase recall, as seen for the additional model detected by manual assessment.
Human mendelian disease is caused by a variety of mutations resulting in complete loss or partial loss or gain of function under various modes of inheritance. The IMPC phenotypes only the null allele in a homozygous state or, in the case of embryonic/perinatal lethality, in the heterozygous state. Thus, IMPC mouse strains are suitable for identification of putative disease-associated genes, as opposed to variant identification, by identifying which genes expressing variants of unknown importance are pathogenic. The 889 human diseases associated with genes orthologous to those of the IMPC mouse model strains were inherited with approximately equal frequency by autosomal dominant (AD) or AR genetics (379 AD compared with 423 AR and 87 unknown/X-linked diseases). The frequency of inheritance by AD and AR genetics was also equivalent for the 185 adult disease-gene associations for which the IMPC mutant mouse line modeled the human disease (82 AD compared with 94 AR and 7 unknown/X-linked diseases). These results indicated that the mouse models effectively model human disease independently of the mode of human inheritance. Human AR disease is likely to be a consequence of a mutation resulting in complete or partial loss of function, for which haploinsufficiency is not adequate to produce symptoms. As would be expected, AR human disease was more frequently modeled by homozygous-null mouse mutants: 65% (61/94) of the AR models were viable and phenotyped as homozygous mice, whereas 35% (33/94) were subviable/lethal as homozygotes, and therefore heterozygous mice were phenotyped. AD inheritance can be attributed to either haploinsufficiency or gain-of-function mutations, and we found that 46% of the dominant human mutations were modeled by heterozygous mouse mutants, in agreement with a haploinsufficiency mechanism for almost half of the diseases.
Interestingly, 227 of the 423 (54%) tested AR associations were homozygous lethal/subviable in mice, thus leading us to consider whether early mortality might occur in people with these diseases or might occur without extensive medical intervention. Lethality matches are not detectable by our automated algorithm, because human lethality is rarely recorded in the disease HPO annotations, and for 74 of the 889 associations (8%), homozygous lethality is the only mouse phenotype that we have detected to date. To address this potential lack of detection, we manually investigated whether the (Fig. 3) . When we included these manually curated lethality matches, 40.5% (360) of the disease models had phenotypic overlap with the 889 disease-associated genes ( Table 1) , and the majority (78%; 279 of 360) represented the first report, to our knowledge, of a candidate mouse model for these diseases. The discovery rate of disease models in our analysis was comparable to that in previous reports on smaller high-throughput mouse phenotyping studies that have found modeling of 46% of 59 and 33% of 42 associations through manual investigation of data 6, 27 .
For cases in which we did not detect a model despite testing for at least one equivalent phenotype (54%; 484), the explanations included differences between human and mouse biology, differences in genetic background, a null allele not being appropriate to model the disease or differing methodologies used for annotation. For example, rarely observed phenotypes for a disease are often recorded in the HPO annotations and would probably fall below the statistical significance threshold if they were similarly nonpenetrant in mice. Finally, there is a slight possibility that some previous descriptions of alleles may have influenced disease modeling in cases in which a hypomorph rather than a null mutant is possible (e.g., the 90 tm1a mutant) or in which a retained neomycin cassette may have altered expression of genes in cis (e.g., 90 tm1a and 10 KOMP1 mutants).
Functional knowledge and candidate genes associated with mendelian diseases
The second major clinical use for the IMPC data is providing new data on the phenotypes and functions of genes. Thus, IMPC has prioritized genes with no known disease associations or minimal Gene Ontology (GO) annotation. On the basis of MGI's literature curation of mutant strains involving any allele type except conditional mutations, 1,830 of the 3,328 genes phenotyped in this IMPC release have not previously had a mouse mutant produced. No GO molecular-function or biologicalprocess annotations were available for 189 genes, whereas another 903 genes had annotations inferred from computational analysis 28 (Fig. 4a) . The phenotypes of these mutant strains provide insights into the functions of a large class of genes (sometimes described as the 'ignorome') 29 , for which there is little or no existing functional information (Supplementary Table 5) .
Examples of candidate genes for human mendelian disease with previously little functional information include family with sequence similarity 53 member B (Fam53b), for which no phenotypic variants had been reported in humans or mice. The gene is differentially expressed in adult definitive erythrocytes compared with primitive erythrocytes, with more than a sixfold log 2 change, as shown in the Expression Atlas (URLs) 30, 31 . Homozygous Fam53b tm1b(EUCOMM)Hmgu knockout mice showed increased mean corpuscular hemoglobin and decreased erythrocyte cell numbers (Fig. 4b,c) , thus suggesting that the gene is involved in hematopoiesis and is a candidate for macrocytic hyperchromic anemias. PhenoDigm identified this gene as having a phenotype mimicking that of Diamond-Blackfan anemia (MIM105650), a group of 15 unique anemias generally attributable to defects in ribosome synthesis but for which known mutations account for only approximately 54% of all affected people 32 . A single functional study has suggested that Fam53b is required for Wnt signaling, which is key in determining cell fate, cell proliferation, stem cell maintenance and formation of the anterior-posterior axis 33 . The Fam53b knockouts thus suggest a new candidate pathway that may account for the 46% of people with Diamond-Blackfan anemia with unknown genetic causes. 
A r t i c l e S
As well as providing fundamental insights into the functions of genes with few or no previous functional annotations, the phenotype analyses are also identifying numerous new candidate disease models that may provide a foundation for relating gene function to disease phenotype. This new data and biological resource may be used to detect novel genotype-to-phenotype associations in diseases for which simply considering existing human data would lead to causative variants being overlooked among the overwhelmingly abundant associated variants of unknown importance, as occurs in many exome-sequencing studies. Over half of diagnosed rare diseases still have no known associated genes, and diagnostic rates in most high-throughput mendelian disease sequencing projects are 20-30%, largely because of a lack of functional information for most genes. The IMPC data can be used to remedy this deficiency and to start achieving better diagnostic rates. As a demonstration of the potential application of IMPC data to the discovery of novel disease-associated genes, we identified candidate genes potentially associated with mendelian diseases through unknown molecular mechanisms, for which broad genetic localization was available in OMIM from previous studies. Our disease-matching algorithm identified 135 associations in which our predicted disease-associated gene was found to be within these loci (Supplementary Table 6 ).
For example, adult mice heterozygous for the Klhdc2 tm1b(EUCOMM)Hmgu allele have a complex syndrome of abnormalities including altered electrocardiogram findings. The phenotypes match the clinical signs described for the AD disease arrhythmogenic right ventricular dysplasia 3 (ARVD3; MIM602086) associated with cardiac arrythmias caused by fibrofatty replacement of the right-ventricle myocardium. Klhdc2 is syntenic with the ARVD3 locus, thus suggesting that it may be a candidate gene. Usmg5-null mice recapitulate the clinical symptoms of muscle weakness and abnormal gait seen in people with the dominant intermediate A form of Charcot-Marie-Tooth disease. The human ortholog USMG5 is located within a 9.8-Mb critical region identified in people with this disease. Whereas the implicated human loci are sometimes megabases in length and encompass hundreds of genes, these examples illustrate how IMPC phenotype data allow for the scoring of candidate genes with disease-causing variants and have important implications for current genetic projects investigating rare diseases through next-generation-sequencing technologies.
DISCUSSION
By analyzing phenotypic similarities between IMPC's mouse strains and human diseases, we provided new disease models and novel functional knowledge for a substantial and growing proportion of proteincoding genes. These models are readily available and can be exploited to study disease mechanisms, to develop new gene therapies and pharmacological treatments, and to improve understanding of gene function. The novelty of the IMPC lies in both the scale of the vision to produce a comprehensive catalog of mammalian gene function across all genes and the non-hypothesis-driven, standardized approach to phenotyping. This resource facilitates novel discoveries about the functions of genes and their roles in diseases, as highlighted above.
The potential of IMPC phenotypic comparisons for prioritizing candidates in human mendelian syndromes is accessible to clinical researchers performing next-generation sequencing-based diagnostics through inclusion within the Exomiser software package, which combines an assessment of variant pathogenicity with gene candidacy on the basis of the similarity of human disease phenotypes to known phenotypic knowledge from humans, mice and fish 34 . Exomiser is being applied within the NIH Undiagnosed Disease Program and Network 35 as well as the 100,000 Genomes Project, which embeds genomics into a national healthcare system. The IMPC goes beyond modeling mendelian syndromes by leveraging its existing global infrastructure to address complex biological questions. IMPC mouse strains are widely used across every major biological system (URLs) and are have been used in SNP validation studies of complex traits in both humans and mice [36] [37] [38] [39] [40] [41] . Such studies will be supported by ongoing work using the IMPC phenotyping pipeline to characterize the eight founder inbred mouse strains for the collaborative cross-resource used in the study of complex traits and in targeted noncoding mutant mouse strains (11 microRNAs and 4 long intervening noncoding RNAs in the current data release) to study regulatory activities. Other collaborative multicenter, efforts are using IMPC mouse strains to study gene function in hearing, vision, metabolism and pervasive sexual dimorphism. Starting in 2017, a substantial fraction (~15%) of mutant strains will be rephenotyped in mice at 12-18 months of age to identify genes involved with late-onset disease.
A major change in our strategy has been the adoption of CRISPRbased methods to increase the production rate and the opportunity to characterize strains containing the same single-nucleotide variants or indels as those in human patients. For example, the MRC Genome Editing Mice for Medicine (GEMM) service is characterizing patient variants identified through whole-genome sequencing by the 100,000 Genomes Project to functionally validate variants of unknown importance and/or facilitate mechanistic and therapeutic studies in collaboration with clinicians and researchers. Generation of these precision models is key to the development of new therapies for rare disease, a process lagging behind the discovery of new disease-associated genes. The approach will be expanded in the coming years to characterize candidate noncoding regulatory variants in undiagnosed 100,000 Genomes Project cases as well as other large-scale sequencing projects such as the Undiagnosed Disease Program and Network. We believe that many of the lessons that we have learned in establishing In b, female control, n = 597 mice; female homozygous, n = 8; male control, n = 635; male homozygous, n = 8; linear mixed-effects model without weight, P = 2.81 × 10 −11 ). In c, female control, n = 598; female homozygous, n = 8; male control, n = 634; male homozygous, n = 9; linear mixed-effects model without weight, P = 0), consistent with Diamond-Blackfan anemia (MIM105650). In b and c, box limits, first and third quartiles; line, median; whiskers, minimum and maximum values; asterisks, significant difference between mutant and same-sex controls, mixed-effects-model P < 0.0000. the IMPC will also be of value in recently launched precisionmedicine efforts, whose goals are to improve treatment through the customization of healthcare according to the genomic information of individual patients and environmental factors. Harmonization of phenotypic traits captured in diverse formats across multiple centers will be critical to the stratification of disease populations for improved treatment as well as using model-organism data to better identify disease-causing gene variants.
Whereas advances in technologies based on CRISPR and induced pluripotent stem cells have vastly expanded researchers' toolkits, the work of the IMPC highlights the continuing importance of mouse models in understanding disease mechanisms. Mice are vertebrate mammals with physiological characteristics that recapitulate those of all major human biological systems, thus allowing the study of processes that cannot be investigated in vitro, including the effects of behavioral, inflammatory, endocrine and sex-specific processes on disease. Whereas CRISPR-based methodologies now allow for genome engineering in nearly every species, mice have other characteristics that have made them a widely used model organism for over a century. Inbred mouse strains such as the C57BL/6N strain used by the IMPC have standardized, uniform genetic backgrounds that decrease phenotypic variability, and most strains have a 2-year lifespan that allows for comprehensive studies in a timely manner.
Reproducibility of results in translational studies is a major issue, and we found that the overlap of phenotypes between IMPC mouse strains and previously published mutant strains was in line with results from other studies investigating reproducibility. This finding highlights the importance of high-quality phenotype annotation of human clinical records and mouse phenotypes and demonstrates the importance of open sharing of data. Toward this end, the IMPC adheres to the ARRIVE guidelines for reproducibility of animal-model experiments, including making all data available and allowing for transparent statistical analysis via free distribution of our PhenStat software 12 .
In conclusion, the IMPC has established an ever-expanding knowledge base of mammalian gene function, a large resource of novel disease models and the capacity for functional validation of variants identified in disease sequencing projects. This information should be of great value to the human disease research community. with reported in utero or early deaths (before two years of age) and coded these in Supplementary Table 1 as yes-lethal (Y-L), thus indicating that for some human cases with mutations for these genes, the phenotype of human lethality matched the phenotype of mouse subviability. We also screened for OMIM records with severe congenital defects and/or rapid progression of early-onset severe disease in human patients requiring substantial medical support for survival. Mice with similar phenotypes would not be likely to survive through weaning in the absence of medical support and therefore were scored as yes-probable lethal (Y-PL), thus indicating a probable match of the human phenotype to the mouse subviable phenotype.
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Matching candidate-gene phenotypes to human traits from OMIM linkage and cytogenetic findings. Diseases with no known molecular mechanism but a narrowed-down cytogenetic region containing the likely causative gene were extracted from OMIM (accessed 2 September 2016). Ensembl was used to identify the human genes within these regions and their mouse orthologs retrieved from HomoloGene. The overlaps between these genes and candidates from the PhenoDigm analysis of the same disease were then flagged within our database and are highlighted in both our portal and Supplementary Tables 1-6 .
Identifying novel gene-phenotype relationships from the IMPC database. An online tool in the IMPC portal (URLs) imports GO annotations daily from the Quick GO resource 45 and categorizes them on the basis of the evidence codes assigned by GO curators. Annotations were analyzed on 24 March 2017. We started with 2,668 genes that had IMPC nonlethal phenotypes. Categories incorporated the following evidence codes:
Experimental: inferred from experiment (EXP), inferred from direct assay (IDA), inferred from physical interaction (IPI), inferred from mutant phenotype (IMP), inferred from genetic interaction (IGI) and inferred from expression pattern (IEP).
Curated computational: inferred from sequence or structural similarity (ISS), inferred from sequence orthology (ISO), inferred from sequence alignment (ISA), inferred from sequence model (ISM), inferred from genomic context (IGC), inferred from biological aspect of ancestor (IBA), inferred from biological aspect of descendant (IBD), inferred from key residues (IKR), inferred from rapid divergence (IRD) and inferred from reviewed computational analysis (RCA).
Automated electronic: inferred from electronic annotation (IEA), traceable author statement (TAS), nontraceable author statement (NAS) and inferred by curator (IC).
No biological data available: no biological data available (ND) and not listed as a gene in GO (no evidence code).
Ethical approval. Mouse production, breeding and phenotyping at each center was done in compliance with each center's ethical animal care and use guidelines in addition to the applicable licensing and accrediting bodies, in accordance with the national legislation under which each center operates. Details of each center's ethical review organization, processes and licenses are provided in Supplementary Table 7 . All efforts were made to minimize suffering by considerate housing and husbandry. All phenotyping procedures were examined for potential refinements disseminated throughout the IMPC. Animal welfare was assessed routinely for all mice.
Code availability. The automated phenotype comparisons were performed with the open-source OWLtools package provided by the Monarch Initiative.
Data availability. All data presented here are openly available from the IMPC portal via our FTP site (ftp://ftp.ebi.ac.uk/pub/databases/impc/latest/). We also provide regular data exports to the MGI group, which provides public access to all available mouse data, and the Monarch Initiative, which integrates genotype-phenotype data from humans and numerous other species.
